HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PD 142893

functional antagonist of endothelin-stimulated vasoconstriction

Also Known As:

Ac-Dip-Leu-Asp-Ile-Ile-Trp; PD-142893; acetyldiphenylalanyl-leucyl-aspartyl-isoleucyl-isoleucyl-tryptophan

Networked: 5 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - PD 142893: 5

Experts

1.	Chen, Wei: 1 article (10/2018)
2.	Li, Tao: 1 article (10/2018)
3.	Liu, Liang-Ming: 1 article (10/2018)
4.	Zhang, Zi-Sen: 1 article (10/2018)
5.	Amon, Michaela: 1 article (05/2007)
6.	Bächle, Annick: 1 article (05/2007)
7.	Harder, Yves: 1 article (05/2007)
8.	Menger, Michael D: 1 article (05/2007)
9.	Mörsdorf, Philipp: 1 article (05/2007)
10.	Pittet, Brigitte: 1 article (05/2007)

Related Diseases

1.	Ventricular Premature Complexes (Premature Ventricular Contraction) 10/01/1996 - "We observed (1) in hearts treated with ramiprilat (100 nmol/L) or captopril (5 mumol/L), a significant reduction of ET-1 secretion under all three experimental conditions and fewer ventricular extrasystoles during reperfusion; (2) increased ET-1 secretion and numerous tachyarrhythmic events in the presence of ACE inhibitor and a bradykinin B2 receptor antagonist, icatibant (100 nmol/L); (3) an almost-complete suppression of reperfusion arrhythmias when an ET receptor antagonist, ie, SB 209670 (5 mumol/L) or PD 142893 (200 nmol/L), was infused together with ACE inhibitor and icatibant; and (4) SB 209670 alone to be equally antiarrhythmic as ACE inhibitors. "
2.	Ischemia 08/01/1997 - "The results from this study show that a mixed ETab endothelin antagonist, PD-142893, infused before ischemia and during reperfusion at a dose which virtually abolished the vasoconstriction produced by a high concentration of exogenous endothelin-1, had no effect on ischemia/reperfusion-induced vasoconstriction in this model. " 05/01/2007 - "ET-receptor blockers were administrated intraperitoneally 30 min before induction of ischemia, as well as daily during the subsequent 4-day period, including (1) BQ-123, a specific ET-A-receptor antagonist (ET-A = 1 mg/kg), (2) BQ-788, a selective ET-B-receptor antagonist (ET-B = 1 mg/kg), and (3) PD-142893, a nonselective ET-AB-receptor antagonist (ET-AB = 0.5 mg/kg). "
3.	Shock 10/01/2018 - "The iNOS and ET-1 inhibitors, aminoguanidine (20 mg/kg) and PD-142893 (0.02 mg/kg), respectively, induced significant improvements in vascular reactivity and organ perfusion and stabilized the hemodynamic parameters in rabbits subjected to endotoxic shock. "
4.	Hypoxia (Hypoxemia) 12/16/1999 - "In chronic hypoxia (5% O2) alone, BrdU uptake was stimulated (approximately 46% of TH+ cells) relative to normoxia (approximately 30%), but the effect was abolished in the presence of specific (BQ 123) or non-specific (PD 142893) ETA receptor antagonists (10(-5) M). "

Related Drugs and Biologics

1.	Bradykinin B2 Receptor
2.	Captopril (Capoten)
3.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
4.	(1S,2R,3S)- 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)- 4- methoxyphenyl)- 2,3- dihydro- 5- propoxy- 1H-Indene-2-carboxylic acid
5.	icatibant
6.	ramiprilat
7.	Endothelin Receptor Antagonists
8.	Endothelin-1 (Endothelin 1)
9.	cyclo(Trp-Asp-Pro-Val-Leu)
10.	Bromodeoxyuridine (BrdU)